Fig 1: Total abundance of Agrin in the CSF (A) and serum (B) of patients diagnosed with Relapse–remitting multiple sclerosis (RRMS), non-inflammatory diseases of the CNS (N-INF), and with other inflammatory diseases of the CNS (INF), and further sub-divided by gender. The results represent the mean ± SEM and statistical analysis was performed by one-way ANOVA followed by the Tukey’s multiple comparison test, comparing all the indicated conditions (ns, p > 0.05; *p ? 0.05, **p ? 0.01, ***p ? 0.001)
Fig 2: Biomarkers of neuromuscular junctions remodelling in response to 10-day bed restNeural cell adhesion molecule (NCAM)-positive fibres expressed as a percentage of the total numbers of fibres (A). NCAM-positive staining at baseline (BR0) (B), 5 days of bed rest (BR5) (C, D) and 10 days of bed rest (BR10) (E–G). Serum C-terminal agrin fragment (CAF) levels measured at BR0, BR5 and BR10 (H). AGRN gene expression (encoding for agrin) (I); CHRNA1 gene expression (encoding for acetylcholine receptor a1 subunit) (L) and HOMER2 gene expression (encoding for homer2 protein) (M). All RNA transcripts are reported as normalized read count at BR0, BR5 and BR10. Results shown as means ± SD, individual data represented as scatter plots. * P < 0.05 BR10 vs BR0.
Fig 3: Association between carrier status of rs2710873 (AGRN) and; appendicular lean mass (A total, B males, C females), whole body lean mass (D total, E males, F females) and plasma C-terminal agrin fragment (CAF) (G total, H males, I females) in the GenoFit cohort (*p < 0.05, **p < 0.01, ***p < 0.001)
Supplier Page from Abcam for Human Agrin ELISA Kit